Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 87.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Fluoxetine vs placebo

Socioeconomic effects · overweight or obese adults

The review found no eligible studies for this question.

1 finding from 1 review

Fluoxetine for adults who are overweight or obese 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs diet and exercise or another antidiabetic drug

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs placebo

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs no intervention

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

Socioeconomic effects

The review found no eligible studies for this question.

1 finding from 1 review

Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table for metformin plus intensive diet and exercise vs intensive diet and exercise

Socioeconomic effects Description: direct medical costs per participant · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 94 participants
Very low